Cyclo Therapeutics

Cyclo Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing drugs for patients and families suffering from diseases through science and innovation. The company's Trappsol® Cyclo™ is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick disease type C (a rare and fatal genetic disorder). The company is planning early clinical trials using Trappsol® Cyclo™ intravenous injection for Alzheimer's disease, based on an expanded access program for late-onset Alzheimer's disease. Other indications for the active ingredient in Trappsol® Cyclo™ are currently under development.